Pharmacodynamics of dose-escalated 'front-loading' polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 8, 2017, Pages 2297-2303

  Smith, Nicholas M ^a   Bulman, Zackery P ^a   Sieron, Arthur O ^b   Bulitta, Jürgen B ^c   Holden, Patricia N ^a   Nation, Roger L ^d   Li, Jian ^d   Wright, Gerard D ^b   Tsuji, Brian T ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMYXIN B; ANTIINFECTIVE AGENT; ESCHERICHIA COLI PROTEIN; MCR-1 PROTEIN, E COLI;

ADULT; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG MECHANISM; ESCHERICHIA COLI; GROWTH REGULATION; HOLLOW FIBER; HUMAN; LOADING DRUG DOSE; MCR 1 GENE; NONHUMAN; PLASMID; DRUG EFFECTS; ESCHERICHIA COLI INFECTION; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; THEORETICAL MODEL;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MODELS, THEORETICAL; POLYMYXIN B;

EID: 85027126651     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx121     Document Type: Article

References (26)

1. Collignon PC, Conly JM, Andremont A et al. World Health Organization ranking of antimicrobials according to their importance in human medicine: a critical step for developing risk management strategies to control antimicrobial resistance from food animal production. Clin Infect Dis 2016; 63: 1087-93
2. Zeng KJ, Doi Y, Patil S et al. Emergence of the plasmid-mediated mcr-1 gene in colistin-resistant Enterobacter aerogenes and Enterobacter cloacae. Antimicrob Agents Chemother 2016; 60: 3862-3
3. McGann P, Snesrud E, Maybank R et al. Escherichia coli harboring mcr-1 and blaCTX-M on a novel IncF plasmid: first report of mcr-1 in the United States. Antimicrob Agents Chemother 2016; 60: 4420-1
4. Liu Y-Y, Wang Y, Walsh TR et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 2016; 16: 161-8
5. Mediavilla JR, Patrawalla A, Chen L et al. Colistin-and carbapenemresistant Escherichia coli harboringmcr-1 and blaNDM-5, causing a complicated urinary tract infection in a patient from the United States. mBio 2016; 7: e01191-16
6. Falgenhauer L, Waezsada SE, Yao Y et al. Colistin resistance gene mcr-1 in extended-spectrum β-lactamase-producing and carbapenemase-producing Gram-negative bacteria in Germany. Lancet Infect Dis 2016; 16: 282-3
7. Poirel L, Kieffer N, Liassine N et al. Plasmid-mediated carbapenem and colistin resistance in a clinical isolate of Escherichia coli. Lancet Infect Dis 2016; 16: 281
8. Mulvey MR, Mataseje LF, Robertson J et al. Dissemination of the mcr-1 colistin resistance gene. Lancet Infect Dis 2016; 16: 289-90
9. Tsuji BT, Landersdorfer CB, Lenhard JR et al. Paradoxical effect of polymyxinB: highdrugexposureamplifies resistance inAcinetobacter baumannii. Antimicrob Agents Chemother 2016; 60: 3913-20
10. Rao GG, Ly NS, Haas CE et al. New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease. Antimicrob Agents Chemother 2014; 58: 1381-8
11. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fifth Informational Supplement M100-S25. CLSI, Wayne, PA, USA, 2015
12. Lenhard JR, Bulitta JB, Connell TD et al. High-intensitymeropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii. J Antimicrob Chemother 2016; 72: 153-65
13. Cheah S-E, Bulitta JB, Li J et al. Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media. J Pharm Biomed Anal 2014; 92: 177-82
14. Sandri AM, Landersdorfer CB, Jacob J et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013; 57: 524-31
15. Cheah S-E, Johnson MD, Zhu Y et al. Polymyxin resistance in Acinetobacter baumannii: genetic mutations and transcriptomic changes in response to clinically relevant dosage regimens. Sci Rep 2016; 6: 26233
16. Bulitta JB, Bingolbali A, Shin BS et al. Development of a new pre-and post-processing tool (SADAPT-TRAN) for nonlinearmixed-effects modeling in S-ADAPT. AAPS J 2011; 13: 201-11
17. Bauer RJ. S-ADAPT/MCPEM User's Guide. Berkeley, CA, USA: Biomedical Simulation Resource, 2011
18. Bulitta JB, Yang JC, Yohonn L et al. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother 2010; 54: 2051-62
19. Mahamad Maifiah MH, Cheah SE, Johnson MD et al. Global metabolic analyses identify key differences in metabolite levels between polymyxin-susceptible and polymyxin-resistant Acinetobacter baumannii. Sci Rep 2016; 6: 22287
20. Baron S, Hadjadj L, Rolain JM et al. Molecular mechanisms of polymyxin resistance: knowns and unknowns. Int J Antimicrob Agents 2016; 48: 583-91
21. CastanheiraM, GriffinMA, Deshpande LMet al. Detection ofmcr-1among Escherichia coli clinical isolates collected worldwide as part of the SENTRY Antimicrobial Surveillance Program in 2014 and 2015. Antimicrob Agents Chemother 2016; 60: 5623-4
22. Doumith M, Godbole G, Ashton P et al. Detection of the plasmidmediated mcr-1 gene conferring colistin resistance in human and food isolates of Salmonella enterica and Escherichia coli in England and Wales. J Antimicrob Chemother 2016; 71: 2300-5
23. Coetzee J, Corcoran C, Prentice E et al. Emergence of plasmid-mediated colistin resistance (MCR-1) among Escherichia coli isolated from South African patients. SAfrMedJ 2016; 106: 35-6
24. Bergen PJ, Bulman ZP, Landersdorfer CB et al. Optimizing polymyxincombinations against resistantGram-negative bacteria. Infect Dis Ther 2015;4: 391-415
25. Wright GD. Antibiotic adjuvants: rescuing antibiotics from resistance. TrendsMicrobiol 2016; 24: 862-71
26. HackelM, Lister T, Parr TR Jr et al. In vitro activity of Spr741 against recent clinical isolates of Escherichia coli and Klebsiella pneumoniae. In: Abstracts of ASM Microbe 2016, Boston, MA, USA. Abstract Number 500. American Society forMicrobiology, Washington, DC, USA